Tobacco heavyweight Altria has launched a significant legal challenge against the United States International Trade Commission (ITC). In a federal court filing in Virginia on Monday, the company, alongside its electronic cigarette subsidiary NJOY, alleges unconstitutional practices in the appointment of the commission’s administrative judges. This legal maneuver represents a strategic counteroffensive in a high-stakes battle over the future of the lucrative vaping market.
Patent Dispute Prompts Aggressive Defense
The lawsuit stems from a complaint filed with the ITC in August by rival Juul Labs. Juul alleged that NJOY’s vaporizer products infringe upon its patents, leading the trade commission to initiate a formal investigation in September. A finding against NJOY could deal a severe blow to Altria’s strategic push into the e-vapor sector.
Altria’s response challenges the ITC’s fundamental procedures. The company’s legal argument centers on the Appointments Clause of the U.S. Constitution, contending that ITC administrative judges qualify as “inferior officers.” Consequently, their appointments should be made by the President, a court of law, or a head of department, rather than by the ITC chairman himself, as is current practice. By targeting the legitimacy of the judges, Altria aims to derail the patent infringement investigation entirely.
This legal fight is crucial for Altria’s long-term “Moving Beyond Smoking” initiative. The acquisition of NJOY is a cornerstone of this strategy, designed to diversify the company’s revenue streams away from its traditional, declining cigarette business.
Should investors sell immediately? Or is it worth buying Altria?
Solid Financials Support Legal Battle
Altria’s ability to mount such an aggressive legal defense is underpinned by its robust financial performance. The corporation released strong quarterly results at the end of October, showing a 3.6 percent increase in adjusted earnings per share. Demonstrating confidence in its financial health, management doubled its share repurchase authorization to $2 billion and raised its quarterly dividend.
Looking forward, Altria provided earnings guidance for the full year 2025, projecting adjusted EPS in the range of $5.37 to $5.45. This forecast represents anticipated growth of 3.5 to 5.0 percent. The company’s longer-term outlook through 2028 targets mid-single-digit average annual growth in earnings per share.
Despite this financial strength, Altria navigates a complex landscape. The e-cigarette market faces significant regulatory uncertainty and is flooded with illegal products. The legal challenge from Juul adds another layer of risk. These headwinds are compounded by the persistent, structural decline of the core cigarette market, a trend that even savvy financial management cannot reverse.
Ad
Altria Stock: Buy or Sell?! New Altria Analysis from November 10 delivers the answer:
The latest Altria figures speak for themselves: Urgent action needed for Altria investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 10.
Altria: Buy or sell? Read more here...









